CDC invokes an existing contract option to choose the US’ largest drug distributor
Saying it is “expanding an existing partnership with the Centers for Disease Control,” the Irving, TX firm has announced its designation as the “centralized” distributor of future Covid-19 vaccines. “We are honored that the U.S. government has asked McKesson to play a key role in the effort to distribute COVID-19 vaccines,” said CEO Brian Tyler in a statement.
In all likelihood, multiple other distributors will be involved as well, possibly as vaccines are cross-docked from McKesson facilities to those of other distributors. That is the pattern for the seasonal flu vaccine, where nearly 200 million dosages move rapidly into hospitals, clinics, retail pharmacies and public health facilities each year. One complication of the Covid-19 process is that some or all of the vaccines will require refrigerated (or possibly deep frozen) storage and transport—it depends on which vaccines ultimately are cleared for administration.
McKesson has been the lead distributor of the CDC’s Vaccines for Children Program (VFC), based on a competitive 2016 contract award. VFC provides vaccines for Medicaid and other underinsured children.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.